The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 37 of the 55 sources its claims cite were checked for support.
Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight
Open accessAbstract
mice, were largely maintained during spaceflight. Systemic inhibition of MSTN/activin A signaling using a soluble form of the activin type IIB receptor (ACVR2B), which can bind each of these ligands, led to dramatic increases in both muscle and bone mass, with effects being comparable in ground and flight mice. Exposure to microgravity and treatment with the soluble receptor each led to alterations in numerous signaling pathways, which were reflected in changes in levels of key signaling components in the blood as well as their RNA expression levels in muscle and bone. These findings have implications for therapeutic strategies to combat the concomitant muscle and bone loss occurring in people afflicted with disuse atrophy on Earth as well as in astronauts in space, especially during prolonged missions.
Overview
CoChat Summary
## TL;DR
This mouse ISS study tested whether blocking myostatin/activin A signaling with ACVR2B/Fc or genetic Mstn deletion could protect against microgravity-induced muscle and bone loss. The paper reports that ACVR2B/Fc significantly increased lean mass and bone measures in flight mice and helped restore both muscle and bone after return to Earth.
## Key findings
- Muscle loss from spaceflight: In wild type mice exposed to microgravity for 33 days, lean body mass was 9% lower, and weights of the pectoralis, triceps, quadriceps, gastrocnemius/plantaris, and soleus were 8%, 8%, 15%, 14%, and 18% lower, respectively, than ground controls.
- ACVR2B/Fc improved muscle growth in flight: In flight mice, lean body mass increased by 27% over 22 days after ACVR2B/Fc treatment, compared with 18% in ground mice over the same interval; individual muscle weights at return were significantly higher than in uninjected flight mice.
- Bone loss from spaceflight and protection by ACVR2B/Fc: In uninjected flight mice, whole-body, left femur, and right femur BMD fell by 8%, 11%, and 8% over 22 days in microgravity. ACVR2B/Fc increased BMD in ground mice by 4%, 10%, and 9% and brought BMD in flight mice to levels comparable to uninjected ground mice.
- MicroCT showed strong skeletal protection: In femurs of uninjected flight mice, BV/TV, trabecular thickness, trabecular number, and cortical thickness were reduced by 37%, 8%, 9%, and 9%; ACVR2B/Fc increased these in ground mice by 96%, 10%, 31%, and 12%, and in flight mice the femoral BV/TV and trabecular number were described as nearly indistinguishable from ACVR2B/Fc-treated ground mice.
- Recovery after return to Earth: After 2 weeks on Earth, untreated mice recovered muscle mass to baseline, but ACVR2B/Fc further increased muscle weights to 39%, 36%, 34%, 26%, and 20% above baseline for pectoralis, triceps, quadriceps, gastrocnemius/plantaris, and soleus, respectively; bone mass also showed conservation or gain with treatment.
## Methods
- Design and sample: The study sent 40 female mice to the ISS in five groups of eight: untreated wild type, ACVR2B/Fc-treated wild type, and Mstn−/− mice, plus additional wild type groups kept on Earth for postflight recovery; there were also 24 ground control mice matched to flight conditions.
- Intervention and timing: ACVR2B/Fc was administered intraperitoneally at 175 μg per injection on scheduled days before/during/after flight; mice were analyzed either at live animal return or after 14 days of recovery on Earth.
- Main analyses: The paper used DXA, microCT, RNAseq, SomaScan proteomics, and ELISA to assess muscle, bone, and pathway changes.
## Limitations
- The authors state that additional studies will be required to understand the basis of the unexpected higher humerus BMD seen early in flight, so that result remains unexplained in the paper.
- They state they did not measure body water content, so the apparent rapid postflight muscle recovery could partly reflect water shifts rather than true tissue recovery.
- Evidence evident from the text: the study used female mice only, so direct generalization to males is not supported by the paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
27 Valid · 1 Not valid · 4 Not checked · 73 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Because TRAIL and RANKL are known to regulate osteoclast differentiation and survival (33–35), these findings suggest that increased RANK (tumor necrosis factor receptor superfamily member 11a) signaling may be involved in the regulation of bone growth and remodeling induced by ACVR2B/Fc.”
§ Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight > Results and Discussion
What the sources say
- Not checked — no full text of the sourcecites [33] source
- Not checked — no full text of the sourcecites [34] source
- Partly supportedcites [35] sourceExperimental — accuracy not yet measured
The citation is attached to the premise about osteoclast differentiation and survival; the ACVR2B/Fc mechanism is the citing authors’ own inference. In “RANKL and TRAIL: ligands from the TNF family” (page unavailable), the source says RANKL–RANK signaling regulates osteoclast differentiation and survival, but it does not establish the same role for TRAIL. (LLM, conf=0.84)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“We showed previously that treatment with ACVR2B/Fc can induce rapid muscle growth (13), and indeed, the decoy receptor increased lean body mass in ground mice by 11% in just 12 d (Fig. 1D).”
§ Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight > Results and Discussion
What the sources say
- Supportedcites [13] source
The citation is attached to the statement that ACVR2B/Fc can induce rapid muscle growth. The source’s Results and Discussion report that its maximal effect was reached after two injections spaced one week apart. The 11% increase in lean body mass over 12 days is attributed to the citing paper’s Fig. 1D, not to this source. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Interestingly, BMD in the humerus was not reduced in flight mice during this 22 d period, consistent with the differential effects of microgravity on the femur and humerus reported in rats (26) and humans (27).”
§ Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight > Results and Discussion
What the sources say
- Supportedcites [26] source
The citation is attached to the differential effects on femur and humerus in rats, not to the citing authors’ observation about mice during a 22-day period. The Results sections report lower femur BMD in flight rats but no significant effect of spaceflight on humerus BMD. (LLM, conf=0.93)
- Supportedcites [27] source
The citation is attached to the comparison with humans, not the citing paper’s finding in 22-day flight mice. In Results, under “Skeletal site-specific changes in bone density” (page unavailable), the source reports substantially greater bone loss in the lower limbs than in the upper-limb/thorax region of space travelers, supporting the stated differential effect. (LLM, conf=0.89)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The dual ability of ACVR2B/Fc to promote muscle growth and to increase bone density has suggested the possibility that this therapeutic strategy may be particularly useful to combat simultaneously comorbid muscle and bone loss, and indeed, this strategy has been shown to be effective in a mouse model of osteogenesis imperfecta, which is characterized by both muscle atrophy and bone fragility (21,”
§ Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight > Abstract
What the sources say
- Supportedcites [21] source
The Results (page not supplied) report significant increases in trabecular bone measures and in several muscle weights after ACVR2B treatment of oim mice. The Introduction identifies this model as having deficits in muscle mass and function, while the Discussion describes low bone mass and fractures alongside muscle atrophy. The paper supports effectiveness for increasing bone and muscle mass; it does not establish improved fracture resistance. (LLM, conf=0.91)
- Partly supportedcites [22] sourceExperimental — accuracy not yet measured
The Results report increased skeletal muscle mass with sActRIIB-mFc treatment, and the Discussion reports improved trabecular bone architecture in both OI mouse models. The paper documents bone fragility, but the passages found do not establish that these models are characterized by muscle atrophy; it also reports no reduction in fracture occurrence. (LLM, conf=0.82)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Although advances in exercise devices and nutrition have significantly attenuated the bone mineral density losses observed during prolonged missions on vehicles like the International Space Station (ISS) (23, 24), future exploration missions to destinations like Mars will be significantly longer (∼3 y) and impose mass constraints that will not allow for the same, highly effective exercise”
§ Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight > Abstract
What the sources say
- Supportedcites [23] source
The Abstract states that improved nutrition and resistance exercise attenuated the BMD deficits previously observed after prolonged missions. The Discussion reports that ISS crewmembers with sufficient resistance exercise and adequate nutrition returned from 4-to-6-month missions with BMD seemingly unchanged from baseline in most skeletal regions. Page numbers are not provided in our copy. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [24] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
44 more claims · 2 with their cited sources checked
Create a free account to see all 105 claims and every source verdict.
- It may state two separate claims as one. 36
- Probably not a substantial claim. 30
Citations
Cites
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · cited 1×
“Because TRAIL and RANKL are known to regulate osteoclast differentiation and survival (33 – 35), these findings suggest that increased RANK (tumor necrosis factor receptor superfamily member 11a) signaling may be involved in the regulation of bone growth and remodeling induced by ACVR2B/Fc.…”
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Self-citationLDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development
Gong, Y., Slee, R. B., Fukai, N., Rawadi, G., Roman-Roman, S., Reginato, A. M., Wang, H., Cundy, T., Glorieux, F. H., Lev, D., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00571-2 · Cited by 2,235 · cited 1×
“Given that loss-of-function mutations in the Wnt receptor LRP5 results in low bone mass in both humans (47) and mice (48), the down-regulation of sFRP4, taken together with changes in levels of several Wnt inhibitors, suggests that altered Wnt signaling may play a role in bone loss resulting from exposure to micrograv…”
Double muscling in cattle due to mutations in the myostatin gene
McPherron, A. C., & Lee, S.-J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12457 · Cited by 2,039
Self-citationAptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754 · cited 1×
“We carried out proteomic analysis of plasma using the SomaScan assay, which uses aptamers to measure relative levels of over 5,000 secreted proteins (31).”
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616 · cited 1×
“Signaling is initiated by binding of these ligands to the activin type II receptors, ACVR2 and ACVR2B (17).”
Self-citationSecreted antagonists of the Wnt signalling pathway
Kawano, Y., & Kypta, R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00623 · Cited by 1,584 · cited 2×
“Nevertheless, given that Dickkopfs are secreted proteins capable of antagonizing Wnt signaling by inhibiting the coreceptors LRP5 and LRP6 (43, 44), these findings suggest that increased Wnt signaling may also be involved in the increase in bone mass induced by ACVR2B/Fc.”
A deletion in the bovine myostatin gene causes the double–muscled phenotype in cattle
Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-71 · Cited by 1,556
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399 · cited 1×
“Moreover, a heavily muscled boy was found to carry a mutation in a splice site in theMSTN gene, showing that MSTN plays a similar role in humans as well (12).”
Self-citationClop, A., Marcq, F., Takeda, H., Pirottin, D., Tordoir, X., Bibé, B., Bouix, J., Caiment, F., Elsen, J.-M., Eychenne, F., et al. (2006) · Nature Genetics · doi:10.1038/ng1810 · Cited by 1,260 · cited 1×
“The function of MSTN has been strongly conserved through evolution, as targeted or naturally occurring mutations in cattle (3–5), sheep (6), dogs (7), rabbits (8), rats (9), swine (10), and goats (11) have all been shown to lead to increased muscling.”
Cited by
Wu, M., Wu, S., Chen, W., & Li, Y.-P. (2024) · Cell Research · doi:10.1038/s41422-023-00918-9 · Cited by 445
Sarcopenia, osteoporosis and frailty
Gielen, E., Dupont, J., Dejaeger, M., & Laurent, M. R. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155638 · Cited by 258
Update on the effects of microgravity on the musculoskeletal system
Juhl, O. J., Buettmann, E. G., Friedman, M. A., DeNapoli, R. C., Hoppock, G. A., & Donahue, H. J. (2021) · npj Microgravity · doi:10.1038/s41526-021-00158-4 · Cited by 187
Pathophysiological mechanisms leading to muscle loss in chronic kidney disease
Wang, X. H., Mitch, W. E., & Price, S. R. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00498-0 · Cited by 170
The effects of microgravity on bone structure and function
Man, J., Graham, T., Squires-Donelly, G., & Laslett, A. L. (2022) · npj Microgravity · doi:10.1038/s41526-022-00194-8 · Cited by 184
“Mice N/A 33 • Spaceflight reduced BMD of whole body, and left and right femur by 8%, 11% and 8%, respectively compared to GC • Inhibition of myostatin/activin A signalling increases BMD in spaceflight mice comparable to untreated GC mice Lee et al.(41)”
Metadata
- Authors
- Lee, S.-J., Lehar, A., Meir, J. U., Koch, C., Morgan, A., Warren, L. E., Rydzik, R., Youngstrom, D. W., Chandok, H., George, J., Gogain, J., Michaud, M., Stoklasek, T. A., Liu, Y., & Germain-Lee, E. L.
- Affiliations
- University of Connecticut (US)
- The Jackson Laboratory for Genomic Medicine (US)
- National Aeronautics and Space Administration (US)
- Center for the Advancement of Science in Space (US)
- SomaLogic (United States) (US)
- Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT 06030;
- Corresponding author
- Lee, Se-Jin
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2020-09-08
- Volume
- 117
- Issue
- 38
- Pages
- 23942-23951
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC7519220
- OpenAlex
- W3084261347
- Cited by
- 115
- References
- 54
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 17 · 2023: 21 · 2022: 19 · 2021: 27 · 2020: 3
- FWCI
- 10.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- Funders
- HHS | National Institutes of Health (R01AG052962, R01AR060636)
- Center for the Advancement of Science in Space (UA-2019-031)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Spaceflight effects on biology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Social Sciences › Political Science and International Relations › Space exploration and regulation
- Keywords
- myostatin, activin A, ACVR2B, microgravity, spaceflight, disuse atrophy, muscle atrophy, bone loss, skeletal muscle, bone mass, signaling pathways
- MeSH terms
- Animals, Bone Resorption, Female, Male, Mice, Inbred C57BL, Muscular Atrophy, Space Flight, Signal Transduction, Mice, Knockout, Muscle, Skeletal, Activins, Activin Receptors, Type II, Mice, Myostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight. https://app.cochat.ai/papers/10.1073/pnas.2014716117
- The paper
- Lee, S.-J., Lehar, A., Meir, J. U., Koch, C., Morgan, A., Warren, L. E., Rydzik, R., Youngstrom, D. W., Chandok, H., George, J., Gogain, J., Michaud, M., Stoklasek, T. A., Liu, Y., & Germain-Lee, E. L. (2020). Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2014716117
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.